Agenus Inc (NASDAQ:AGEN) Looses Sheen After Lung Cancer Trial Data Disappoints

Posted by Chris Bell March 21, 2014 0 Comment 1010 views

Agenus Inc (NASDAQ:AGEN) saw its market valuation go down by a double digit margins yesterday. The trigger for the sell off could be traced to the Form 8K filing that the company did with SEC before markets opened yesterday. The filings related to the company updating the regulator about the reversal it has faced, in its phase 3 trials that it was pursuing for its target drug for treating lung cancer in association with GlaxoSmithKline plc (ADR) (NYSE:GSK).

Reversal In Phase 3 Tests

The phase three trials were being conducted by the larger drug maker GlaxoSmithKline plc (ADR) (NYSE:GSK) and it reported yesterday (European time) that its top line results for two parameters were not meeting the end goal objectives, the companies had set for themselves ahead of the initiation of the trails.

Likely To Continue Testing

The large capped multinational held out hope for Agenus Inc (NASDAQ:AGEN), when it indicated that their third party evaluators had determined that the data collected was supportive of continuation of the trail in pursuit of meeting the third end point goal, which if met would mean the test drug compound could still hold commercial value to both companies. The end results for all the three end points are likely to be gathered only by mid 2015.

Origins: From Tree Bark

The potential lung cancer treatment drug has been code named as “Agenus’ SQ-21 Stimulon” had been developed by the small cap drug maker by using extracts from the bark of a tree which was found only in the ever green forests of the Amazon.

Looking Ahead

These disheartening data points from the eagerly awaited test results resulted in the stock of the development stage drug maker plummeting yesterday. Now that the hopes of the drug leading to a commercial launch are largely diminished, the investors and the stake holders of the drug firm would be switching their focus on the next promising drug in their development pipeline.

About Chris Bell

Chris Bell is an investing reporter for GDP Insider. Chris covers financial markets and Wall Street, concentrating on developments affecting individual investors and their portfolios. Chris is also over consumer reporter and covers a wide variety of issues ranging from housing to immigration to urban poverty. Chris graduated from the University of Scranton with a degree in Communication and Philosophy. Chris's diligent investigations earned him the honor of being named "Best Reporter" once by the Headliners Foundation of Texas and once by the Houston Press Club.

View all post by Chris Bell Visit author's website

Write Your Comment